Gov­ern­ment-paid ex­perts help­ing in­dus­try at the ta­ble with FDA? Agency spells out guardrails

The FDA-bio­phar­ma in­dus­try re­volv­ing door can some­times spin so fast that it’s dif­fi­cult to keep up with who’s rep­re­sent­ing what in­ter­ests.

While the FDA’s re­views of new drugs are en­tire­ly fund­ed by in­dus­try, the agency is fa­mous­ly the on­ly drug reg­u­la­tor in the world that ac­tu­al­ly per­forms its own analy­ses of the raw da­ta gen­er­at­ed by new bio­phar­ma spon­sor tri­als, and has al­ways tak­en its ob­jec­tiv­i­ty se­ri­ous­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER